New treatments for severe lung inflammation in older adults
Official title: Development of Novel Second Generation Anti-inflammatory Substrate-selective p38 MAP Kinase Inhibitors as Therapy for Acute Respiratory Distress Syndrome
Funded at Baltimore VA Medical Center · NIH-11098473 · Data updated 2026-11-12
This study is working on new medications to help people with Acute Respiratory Distress Syndrome (ARDS), especially those who have had respiratory infections like COVID-19, by creating drugs that can reduce harmful inflammation in the lungs while keeping the good stuff intact.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baltimore VA Medical Center NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 1, 2018 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| NIH project number | 5I01BX004270-07 |
| Project ID | NIH-11098473 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults, particularly those over 65, who are at risk for or suffering from Acute Respiratory Distress Syndrome.
✕Less likely to help
Patients who are younger than 65 or do not have risk factors for ARDS may not benefit from this research.
What this research studies
This research focuses on developing new medications to treat Acute Respiratory Distress Syndrome (ARDS), a serious condition that can occur after respiratory infections like COVID-19. The team is creating specialized inhibitors that selectively target specific pathways involved in inflammation, aiming to reduce the harmful effects of ARDS while preserving beneficial processes. By using advanced computer-aided drug design, they have identified promising compounds that may improve lung function and patient outcomes. The goal is to provide effective therapies for patients who currently have limited treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for ARDS, significantly improving survival rates and quality of life for affected patients.
How similar studies have gone: Other research has shown promise in targeting specific pathways in inflammation, suggesting that this approach could be effective, although it is still relatively novel.
Where this research is happening
-
Baltimore VA Medical Center
Baltimore, United States Active
Researchers
- Principal investigator: Hasday, Jeffrey D — Baltimore VA Medical Center
- Study coordinator: Hasday, Jeffrey D
Related research
Other NIH-funded projects on the same topics.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Dead space and inhaled nitric oxide in pediatric ARDS
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
-
Immune, hormone, and muscle energy links to recovery after ARDS
This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>
-
Understanding why some people with severe lung injury get worse and how to tailor therapy
A patient-focused program that looks at why people develop sepsis-associated ARDS and how their bodies respond, with the goal of guiding better, personalized treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.